Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...
Consolidative RT improves OS and event-free survival in DLBCL patients, especially with advanced IPI scores and bulky disease. Patients achieving complete remission do not benefit from RT in terms of ...
In patients with previously untreated diffuse large B-cell lymphoma (DLBCL), polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) demonstrated sustained ...
Researchers at the University of Southampton have identified a new subtype of lymphoma which could pave the way to improved and more targeted treatments for some blood cancer patients. The cancer ...
Please provide your email address to receive an email when new articles are posted on . In this video, Tycel Phillips, MD, discusses initial results of a phase 1b clinical trial focused on treating ...
Please provide your email address to receive an email when new articles are posted on . The trial was presented at Society of Hematologic Oncology’s Annual Meeting. “Combining bispecifics with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback